Abstract
Little is known about the acute and long-term sequelae of COVID-19 and its pathophysiology in African patients, who are known to have a distinct immunological profile compared to Caucasian populations. Here, we established proteomic signatures to define severe outcomes of acute COVID-19 and determined whether proteome signatures during the first week of acute illness predict the risk of post-acute sequelae of COVID-19 (Long COVID) in a low-income country (LIC) setting. Using the Olink inflammatory panel, we measured the expression of 92 proteins in the plasma of COVID-19 patients (n=55) and non-COVID-19 individuals (n=23). We identified distinct inflammatory proteomic signatures in acute severe COVID-19 individuals (n=22) compared to asymptomatic or mild/moderate COVID-19 cases (n=33), and non-COVID-19 controls. Levels of SLAMF1, CCL25, IL2RB, IL10RA, IL15RA, IL18 and CST5 were significantly upregulated in patients with critical COVID-19 illness compared to individuals negative for COVID-19. The cohort was followed for an average of 20 months, and 23 individuals developed Long COVID, based on the WHO’s case definition, while 32 COVID-19 patients recovered fully. Whereas upregulated levels of SLAMF1, TNF, TSLP, IL15RA, IL18, ADA, CXCL9, CXCL10, IL17C, and NT3 at the acute phase of the illness were associated with increased Long COVID risk, upregulated expression of TRANCE was associated with a reduced risk of developing Long COVID. Proteomic expression levels of SLAMF1, IL15RA, and IL18 associated with critical illness during the acute phase of COVID-19 also predicted Long COVID risk. Unravelling the pathophysiology of severe acute COVID-19 and Long COVID before its advent may contribute to designing novel interventions for diagnosing, treating, and monitoring of SARS-CoV-2 infection and its associated acute and long-term consequences.
Competing Interest Statement
DW, GT, and MT, GT received funding from the European and Developing Countries Clinical Trials Partnership (EDCTP), European Union. DW is a Senior EDCTP Research Fellow and is a member of the Strategic and Scientific Advisory Board of the Research Networks for Health Innovations in Sub-Saharan Africa funded by the German Federal Ministry of Education and Research (BMBF). All other authors declare no conflicts of interest. MM is supported by an early investigator award from the Canadian Institutes of Health Research (CIHR) and the Canadian Asthma Allergy and Immunology Foundation (CAAIF), and reports grants from CIHR and Methapharm Specialty Pharmaceuticals, personal fees from AstraZeneca and GlaxoSmithKline, consultant fees from Novartis, outside the submitted work. DB reports grants from the COVID-19 Immunity Task Force/Public Health Agency of Canada, grants from the National Science and Engineering Research Council (NSERC), grants from CIHR, personal fees from AZ Mexico, personal fees for invited presentations from academic institutions, outside the submitted work and is on the board of directors for Lung Health Foundation and has been an expert testimony witness for the Government of Canada.
Funding Statement
This work received grants from the Ethiopian Federal Ministry of Health, Addis Ababa, Ethiopia, and McMaster University, Hamilton, Canada.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed and approved by the Health Research Ethics Review Committee of the Ethiopian Public Health Institute in Ethiopia (EPHI-IRB-282-2020) and the Hamilton Integrated Research Ethics Board (HiREB:16956). Written informed consent was obtained by all participants, or their guardians, for participation in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
All data related to this study will be made available upon request and review.
